Previous close | 0.3500 |
Open | 0.3000 |
Bid | 0.2500 |
Ask | 0.3500 |
Strike | 4.50 |
Expiry date | 2025-01-17 |
Day's range | 0.3000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 637 |
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: H.C. Wainwrigh